# Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.

> **NCT00801437** · — · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 457 (actual)

## Conditions studied

- Glaucoma, Open-angle

## Interventions

- **DRUG:** Xalacom

## Key facts

- **NCT ID:** NCT00801437
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 457 (ACTUAL)
- **Last updated:** 2021-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00801437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00801437, "Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00801437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*